These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30977712)

  • 1. Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey.
    Ford JH; Ye W; Nichols RM; Foster SA; Nelson DR
    J Med Econ; 2019 Sep; 22(9):849-858. PubMed ID: 30977712
    [No Abstract]   [Full Text] [Related]  

  • 2. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine.
    Silberstein SD; Lee L; Gandhi K; Fitzgerald T; Bell J; Cohen JM
    Headache; 2018 Nov; 58(10):1579-1592. PubMed ID: 30375650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
    Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cycling Through Migraine Preventive Treatments: Implications for All-Cause Total Direct Costs and Disease-Specific Costs.
    Ford JH; Schroeder K; Nyhuis AW; Foster SA; Aurora SK
    J Manag Care Spec Pharm; 2019 Jan; 25(1):46-59. PubMed ID: 30044691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Migraine burden and costs in France: a nationwide claims database analysis of triptan users.
    Donnet A; Emery C; Aly S; Allaf B; Cayre F; Mahieu N; Gourmelen J; Levy P; Fagnani F
    J Med Econ; 2019 Jul; 22(7):616-624. PubMed ID: 30836035
    [No Abstract]   [Full Text] [Related]  

  • 7. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study.
    Lipton RB; Munjal S; Buse DC; Bennett A; Fanning KM; Burstein R; Reed ML
    Headache; 2017 Jul; 57(7):1026-1040. PubMed ID: 28603893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment.
    Lombard L; Ye W; Nichols R; Jackson J; Cotton S; Joshi S
    Headache; 2020 Jul; 60(7):1325-1339. PubMed ID: 32510611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database.
    Yu S; Zhang Y; Yao Y; Cao H
    J Headache Pain; 2020 May; 21(1):53. PubMed ID: 32404048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States.
    Varnado OJ; Vu M; Buysman E; Kim G; Allenback G; Hoyt M; Trenz H; Cao F; Viktrup L
    J Manag Care Spec Pharm; 2024 Aug; 30(8):792-804. PubMed ID: 39088336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
    Mitchell MP; Schaecher K; Cannon HE; Speckman M
    J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Depression on Health and Medical Care Utilization and Expenses in US Adults With Migraine: A Retrospective Cross Sectional Study.
    Wu J; Davis-Ajami ML; Kevin Lu Z
    Headache; 2016 Jul; 56(7):1147-60. PubMed ID: 27350407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 3-year follow-up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims-based cohort study in the United States.
    Joshi S; Spargo A; Hoyt M; Panni T; Viktrup L; Kim G; Hasan A; Liu YY; Zakharyan A
    Headache; 2024; 64(7):796-809. PubMed ID: 38898657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey.
    Gibbs SN; Shah S; Deshpande CG; Bensink ME; Broder MS; Dumas PK; Buse DC; Vo P; Schwedt TJ
    Headache; 2020 Jul; 60(7):1351-1364. PubMed ID: 32369201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine.
    Buse DC; Yugrakh MS; Lee LK; Bell J; Cohen JM; Lipton RB
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1334-1343. PubMed ID: 32678721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Munjal S; Buse DC; Fanning KM; Bennett A; Reed ML
    Headache; 2016 Nov; 56(10):1635-1648. PubMed ID: 27731896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis.
    Huang J; Wang X; Jin Y; Lou G; Yu Z
    J Headache Pain; 2024 Apr; 25(1):62. PubMed ID: 38654177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription Patterns and the Cost of Migraine Treatments in German General and Neurological Practices.
    Jacob L; Kostev K
    Pain Pract; 2017 Jul; 17(6):747-752. PubMed ID: 27622427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States.
    Dodick DW; Reed ML; Lee L; Balkaran BL; Umashankar K; Parikh M; Gandhi P; Buse DC
    Headache; 2024 Apr; 64(4):361-373. PubMed ID: 38523435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.